Alnylam Pharmace. buy Needham & Company LLC
Summary
This prediction ended on 05.08.24 with a price of €244.00. With a performance of 45.24% the BUY prediction by Needham___Company_LL was a big success. Needham___Company_LL has a follow-up prediction for Alnylam Pharmace. where he still thinks Alnylam Pharmace. is a Buy. Needham___Company_LL has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Alnylam Pharmace. | -0.674% | -0.674% | 43.037% |
iShares Core DAX® | 1.937% | 1.473% | 18.596% |
iShares Nasdaq 100 | -1.186% | -0.040% | 27.123% |
iShares Nikkei 225® | 1.938% | 4.205% | 17.502% |
iShares S&P 500 | -0.023% | 0.109% | 24.843% |
Comments by Needham___Company_LL for this prediction
In the thread Alnylam Pharmace. diskutieren
In the thread Trading Alnylam Pharmace.